DE60205974D1 - Neue Benzotriazole mit entzündungshemmender Wirkung - Google Patents

Neue Benzotriazole mit entzündungshemmender Wirkung

Info

Publication number
DE60205974D1
DE60205974D1 DE60205974T DE60205974T DE60205974D1 DE 60205974 D1 DE60205974 D1 DE 60205974D1 DE 60205974 T DE60205974 T DE 60205974T DE 60205974 T DE60205974 T DE 60205974T DE 60205974 D1 DE60205974 D1 DE 60205974D1
Authority
DE
Germany
Prior art keywords
inhibitor
new
definitions
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60205974T
Other languages
English (en)
Other versions
DE60205974T2 (de
Inventor
Mark Anthony Dombroski
Ellen Ruth Laird
Michael Anthony Letavic
Kim Francis Mcclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60205974D1 publication Critical patent/DE60205974D1/de
Application granted granted Critical
Publication of DE60205974T2 publication Critical patent/DE60205974T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60205974T 2001-04-04 2002-03-26 Neue Benzotriazole mit entzündungshemmender Wirkung Expired - Fee Related DE60205974T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28133101P 2001-04-04 2001-04-04
US281331P 2001-04-04

Publications (2)

Publication Number Publication Date
DE60205974D1 true DE60205974D1 (de) 2005-10-13
DE60205974T2 DE60205974T2 (de) 2006-06-29

Family

ID=23076827

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205974T Expired - Fee Related DE60205974T2 (de) 2001-04-04 2002-03-26 Neue Benzotriazole mit entzündungshemmender Wirkung

Country Status (9)

Country Link
US (1) US6664395B2 (de)
EP (1) EP1247810B1 (de)
JP (1) JP3832646B2 (de)
AT (1) ATE304009T1 (de)
BR (1) BR0201087A (de)
CA (1) CA2379903C (de)
DE (1) DE60205974T2 (de)
ES (1) ES2247271T3 (de)
MX (1) MXPA02003454A (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1382603B1 (de) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
MXPA05008568A (es) 2003-02-14 2005-11-04 Pfizer Prod Inc Nuevos compuestos anti-inflamatorios triazolo-piridinas.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
WO2004099127A1 (en) * 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
CN1893950A (zh) * 2003-12-18 2007-01-10 辉瑞产品公司 用p38 MAP激酶抑制剂治疗动物急性炎症的方法
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
JO2775B1 (en) * 2008-04-04 2014-03-15 ايلي ليلي اند كومباني 3-indazolil 4-pyridyl isothiazole
CN102131806A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的三唑并吡啶化合物
US20100183600A1 (en) * 2008-12-05 2010-07-22 Arqule, Inc. RAF Inhibitors and Their Uses
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
EP2931883B1 (de) * 2012-12-17 2017-02-01 Allinky Biopharma P38 mapk-inhibitoren zur behandlung von entzündungskrankheiten
EP3015451B1 (de) * 2013-06-25 2018-01-17 Kumiai Chemical Industry Co., Ltd. Verfahren zur herstellung einer nitrobenzolverbindung
CN105481863B (zh) * 2015-12-09 2018-11-02 科贝源(北京)生物医药科技有限公司 2-甲基-6-(4-甲基苯磺酰基)-1,4,5,6-四氢咪唑并[4,5-d][1]苯并氮杂*的合成方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018231745A1 (en) * 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2021101854A1 (en) 2019-11-19 2021-05-27 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN115490646A (zh) * 2022-10-10 2022-12-20 安徽昊帆生物有限公司 3-硝基-1，2，4-三氮唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283753A (en) * 1976-01-01 1977-07-12 Fuji Photo Film Co Ltd Benzotriazole
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
EP0724588B1 (de) 1993-09-17 1999-11-10 Smithkline Beecham Corporation Medikamente bindendes protein
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP2002516325A (ja) 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
DE69903976T2 (de) 1998-12-16 2003-07-24 Aventis Pharma Ltd Heteroaryl-zyklische acetale
US6469018B1 (en) 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds
EP1158985B1 (de) 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
ATE304009T1 (de) 2005-09-15
EP1247810B1 (de) 2005-09-07
CA2379903C (en) 2006-08-01
BR0201087A (pt) 2003-05-27
EP1247810A1 (de) 2002-10-09
MXPA02003454A (es) 2004-07-16
DE60205974T2 (de) 2006-06-29
JP3832646B2 (ja) 2006-10-11
US6664395B2 (en) 2003-12-16
US20030078432A1 (en) 2003-04-24
CA2379903A1 (en) 2002-10-04
JP2002308872A (ja) 2002-10-23
ES2247271T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
DE60205974D1 (de) Neue Benzotriazole mit entzündungshemmender Wirkung
ATE254105T1 (de) Benzamid-derivate und ihre verwendung als cytokine inhibitoren
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60236322D1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
DE60043120D1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
NO995006L (no) Nye forbindelser
CY1107433T1 (el) Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
CA2379560A1 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
BRPI9912726B1 (pt) derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
ID26236A (id) Turunan benzamida untuk pengobatan penyakit yang diperantarai oleh sitokina
NO20021448D0 (no) Nye tiazolo (4,5-D)-pyrimidinforbindelser
CA2299399A1 (en) Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
NO980622D0 (no) Fremgangsmåte og preparater anvendelige for inhibering av <alfa>v<beta>5-formidlet angiogenese
NZ332240A (en) Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) and are therefor useful for treating inflammatory diseases
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
ES2138983T3 (es) Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica.
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DK0587088T3 (da) Substituerede cyclohexan-derivater, fremgangsmåde til deres fremstilling og anvendelsen af forbindelserne til behandling af sygdomme
FR2678271B1 (fr) Derives de pyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee